NKGen Biotech ( (NKGN) ) has released a notification of late filing.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
NKGen Biotech, Inc. has announced a delay in filing its Annual Report on Form 10-K (Yearly Report) for the fiscal year ending December 31, 2024. The delay is primarily due to the timing of management’s first public year-end close process and related administrative matters, which could not be resolved without unreasonable effort or expense. The company expects to file the report within the fifteen-day grace period allowed by Rule 12b-25. NKGen Biotech does not anticipate any significant changes in its financial results compared to the previous fiscal year. The notification was signed by Paul Song, the Chief Executive Officer, indicating ongoing compliance efforts.
More about NKGen Biotech
YTD Price Performance: -76.41%
Average Trading Volume: 3,985,220
Technical Sentiment Signal: Buy
Current Market Cap: $7.34M
See more data about NKGN stock on TipRanks’ Stock Analysis page.